HRP20100240T1 - Polipeptidi za indukciju zaštitnog imunitetnog odgovora protiv staphylococcus aureus - Google Patents

Polipeptidi za indukciju zaštitnog imunitetnog odgovora protiv staphylococcus aureus Download PDF

Info

Publication number
HRP20100240T1
HRP20100240T1 HR20100240T HRP20100240T HRP20100240T1 HR P20100240 T1 HRP20100240 T1 HR P20100240T1 HR 20100240 T HR20100240 T HR 20100240T HR P20100240 T HRP20100240 T HR P20100240T HR P20100240 T1 HRP20100240 T1 HR P20100240T1
Authority
HR
Croatia
Prior art keywords
seq
polypeptide
sequence
amino acid
immunogen
Prior art date
Application number
HR20100240T
Other languages
English (en)
Croatian (hr)
Inventor
S. Anderson Annaliesa
Ute Jansen Kathrin
Kelly Rosemarie
D. Schultz Loren
L. Montgomery Donna
L. Mcclements William
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34107815&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20100240(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of HRP20100240T1 publication Critical patent/HRP20100240T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HR20100240T 2003-07-24 2004-07-22 Polipeptidi za indukciju zaštitnog imunitetnog odgovora protiv staphylococcus aureus HRP20100240T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48984003P 2003-07-24 2003-07-24
US52011503P 2003-11-14 2003-11-14
PCT/US2004/023523 WO2005009379A2 (en) 2003-07-24 2004-07-22 Polypeptides for inducing a protective immune response against staphylococcus aureus

Publications (1)

Publication Number Publication Date
HRP20100240T1 true HRP20100240T1 (hr) 2010-09-30

Family

ID=34107815

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100240T HRP20100240T1 (hr) 2003-07-24 2004-07-22 Polipeptidi za indukciju zaštitnog imunitetnog odgovora protiv staphylococcus aureus

Country Status (23)

Country Link
US (2) US20060177462A1 (enExample)
EP (1) EP1651166B8 (enExample)
JP (1) JP2007502101A (enExample)
KR (1) KR20060065643A (enExample)
AT (1) ATE457737T1 (enExample)
AU (1) AU2004258979B2 (enExample)
BR (1) BRPI0412799A (enExample)
CA (1) CA2532370A1 (enExample)
CY (1) CY1110028T1 (enExample)
DE (1) DE602004025579D1 (enExample)
DK (1) DK1651166T3 (enExample)
ES (1) ES2342778T3 (enExample)
HR (1) HRP20100240T1 (enExample)
IL (1) IL173253A0 (enExample)
IS (1) IS8213A (enExample)
MX (1) MXPA06000854A (enExample)
NO (1) NO20060898L (enExample)
NZ (2) NZ544542A (enExample)
PL (1) PL1651166T3 (enExample)
PT (1) PT1651166E (enExample)
RU (1) RU2337108C2 (enExample)
SI (1) SI1651166T1 (enExample)
WO (1) WO2005009379A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
JP2007528217A (ja) * 2004-02-18 2007-10-11 メルク　エンド　カムパニー　インコーポレーテッド スタヒロコッカス・アウレウスに対する防御免疫応答を誘導するためのポリペプチド
AU2005310981A1 (en) * 2004-10-25 2006-06-08 The University Of Western Ontario Vaccines, compositions and methods based on Staphylococcus aureus iron-regulated surface determinants IsdA, IsdB, and IsdC
GB0526038D0 (en) * 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
WO2007089470A2 (en) * 2006-01-27 2007-08-09 Merck & Co., Inc. Antigen-binding proteins targeting s. aureus orf0657n
US8124108B2 (en) 2007-01-24 2012-02-28 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against Staphylococcus epidermidis
EP2374466B1 (en) * 2007-05-04 2013-08-28 Krönke, Martin Protective staphylococcus aureus vaccine based on cell wall-associated proteins
BRPI0811193A2 (pt) * 2007-05-31 2014-11-11 Merck & Co Inc Proteína de ligação a antígeno isolada, ácido nucleico, célula recombinante, métodos para produzir uma proteína e para proteger ou tratar contra uma infecção por s. aureus em paciente, composição farmacêutica, uso da proteína de ligação a antígeno, e, polipeptídeo.
US8071561B2 (en) 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
KR101661946B1 (ko) 2007-08-31 2016-10-05 유니버시티 오브 시카고 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물
US8758765B2 (en) 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
JP2012509665A (ja) 2008-11-26 2012-04-26 メルク・シャープ・エンド・ドーム・コーポレイション スタフィロコッカス・アウレウス（ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）に対する防御免疫応答を誘導するポリペプチド
SMT202000246T1 (it) 2009-04-03 2020-07-08 Univ Chicago Composizioni e metodi relativi a varianti della proteina a (spa)
AU2010238255B2 (en) 2009-04-14 2014-10-16 Novartis Ag Compositions for immunising against Staphylococcus aureus
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
MX338753B (es) 2009-09-30 2016-04-29 Novartis Ag Conjugacion de polisacaridos capsulares de tipo 5 y de tipo 8 de staphylococcus aureus.
CN109134677A (zh) 2009-10-30 2019-01-04 诺华股份有限公司 金黄色葡萄球菌5型和8型荚膜多糖的纯化
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011113056A1 (en) * 2010-03-12 2011-09-15 The Trustees Of The University Of Pennsylvania Methods for preventing and treating staphylococcus aureus colonization, infection, and disease
US8821894B2 (en) 2010-07-02 2014-09-02 The University Of Chicago Compositions and methods related to protein A (SpA) variants
EP2593133A4 (en) 2010-07-13 2014-11-26 Merck Sharp & Dohme STAPHYLOCOCCUS AUREUS SURFACE PROTEIN SA1789 AND PROTECTIVE VACCINE BASED ON IT
EP2638058B1 (en) 2010-11-12 2017-01-11 Merck Sharp & Dohme Corp. Enolase peptide conjugate vaccines against staphylococcus aureus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
MX2014002363A (es) 2011-09-01 2014-04-14 Novartis Ag Formulaciones de antigenos de staphylococcus aureus con adyuvante.
US9527892B2 (en) 2011-10-31 2016-12-27 Merck Sharp & Dohme Corp. Protective vaccine based on Staphylococcus aureus SA2451 protein
EP2867254B1 (en) 2012-06-27 2017-10-25 F. Hoffmann-La Roche AG Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
MX354862B (es) 2012-06-27 2018-03-23 Hoffmann La Roche Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes.
WO2014011645A1 (en) 2012-07-10 2014-01-16 Merck Sharp & Dohme Corp. Protective vaccine based on staphylococcus aureus sa2493 protein
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
BR112021022902A2 (pt) 2019-05-14 2022-01-25 Univ Chicago Métodos e composições que compreendem variantes de proteína a staphylococcus (spa)
US12528882B2 (en) 2019-09-13 2026-01-20 The University Of Chicago Methods and compositions for treating staphylococcal infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
AU5867100A (en) * 1999-05-03 2000-12-12 Medarex, Inc. Human antibodies to staphylococcus aureus
GB0014907D0 (en) * 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
WO2002102829A2 (en) * 2001-06-15 2002-12-27 Inhibitex, Inc. Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
WO2003042249A2 (en) * 2001-11-12 2003-05-22 Novo Nordisk A/S Peptide purification by means of metal ion affinity chromatography
CA2469132A1 (en) * 2001-12-11 2003-07-03 Merck & Co., Inc. Staphylococcus aureus exopolysaccharide and process
US20080050361A1 (en) * 2004-10-25 2008-02-28 Heinrichs David E Staphylococcus aureas specific anti-infectives
CA2637598A1 (en) * 2006-01-18 2007-02-14 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins

Also Published As

Publication number Publication date
US20100247561A1 (en) 2010-09-30
ES2342778T3 (es) 2010-07-14
EP1651166A2 (en) 2006-05-03
JP2007502101A (ja) 2007-02-08
DK1651166T3 (da) 2010-05-31
DE602004025579D1 (de) 2010-04-01
ATE457737T1 (de) 2010-03-15
MXPA06000854A (es) 2006-03-30
IS8213A (is) 2005-12-30
EP1651166A4 (en) 2008-03-05
NZ570750A (en) 2009-12-24
NO20060898L (no) 2006-04-24
EP1651166B8 (en) 2010-05-19
CA2532370A1 (en) 2005-02-03
NZ544542A (en) 2009-01-31
IL173253A0 (en) 2006-06-11
RU2006105498A (ru) 2006-09-10
AU2004258979B2 (en) 2007-12-06
WO2005009379A2 (en) 2005-02-03
RU2337108C2 (ru) 2008-10-27
BRPI0412799A (pt) 2006-09-26
PT1651166E (pt) 2010-04-23
KR20060065643A (ko) 2006-06-14
WO2005009379A3 (en) 2006-11-30
AU2004258979A1 (en) 2005-02-03
PL1651166T3 (pl) 2010-08-31
CY1110028T1 (el) 2015-01-14
EP1651166B1 (en) 2010-02-17
US20060177462A1 (en) 2006-08-10
SI1651166T1 (sl) 2010-06-30

Similar Documents

Publication Publication Date Title
HRP20100240T1 (hr) Polipeptidi za indukciju zaštitnog imunitetnog odgovora protiv staphylococcus aureus
CN101516395B (zh) 抗屈曲病毒感染的疫苗
JP2007502101A5 (enExample)
PH12021550030A1 (en) Nucleotide sequences encoding peptide antigens of sars-cov-2 virus and use thereof
JP2009540801A5 (enExample)
EP1578922A2 (en) Replikin peptides in rapid replication of glioma cells and in influenza epidemics
CA3233697A1 (en) Recombinant fusion protein derived from hr region of s2 protein of sars-cov-2 and application of recombinant fusion protein
JP7146926B2 (ja) Ｃｄ４ヘルパーｔ細胞エピトープの融合ペプチドおよびそのワクチン
ES2366176T3 (es) Citocinas aviares novedosas y secuencias genéticas que codifican para las mismas.
IE871169L (en) Vaccine against varicella-zoster virus
JP2012517239A5 (enExample)
CN113603754B (zh) 一种水禽h5n8亚型流感病毒ha重组蛋白及其制备方法与应用
JPS59501866A (ja) 腸内ウイルスに対するワクチン接種に有用なポリペプチド
CN107698665B (zh) 一种抗病毒多肽、编码基因、载体、宿主菌及应用
TW200716166A (en) Lawsonia intracellularis immunological proteins
HRP20100340T1 (hr) Polipeptidi koji imaju antimikrobno djelovanje i polinukleotidi koji ih kodiraju
CN103352047A (zh) 旋毛虫肌幼虫es抗原基因疫苗及其制备方法
CN102241748A (zh) D29分枝杆菌噬菌体来源的pk34多肽及其应用
Shao et al. DNA fragment encoding human IL-1β 163–171 peptide enhances the immune responses elicited in mice by DNA vaccine against foot-and-mouth disease
CN1035126A (zh) 编码狂犬病毒糖蛋白的基因片段及用此片段制备狂犬病毒糖蛋白的方法
CN101544693A (zh) 重组胸腺素α1二串体蛋白及其制备方法
KR101127926B1 (ko) 해수어 이리도바이러스 항원성 펩타이드 및 이를 이용한 이리도바이러스 예방용 백신
CN110386965B (zh) 一种坦布苏病毒e蛋白b细胞表位及其编码基因和应用
CN101940786A (zh) 副猪嗜血杆菌免疫原性蛋白基因PilA的应用
CN113248576A (zh) 一种针对冠状病毒的核酸疫苗及其制备方法